This document is a patent application (US20260083742A1) filed with the USPTO on December 1, 2025. It describes methods for treating cancer by administering azenosertib, a WEE1 inhibitor, to patients identified as having homologous recombination repair deficiency (HRD), which is proposed as a predictive biomarker. The application lists several inventors and includes CPC classifications related to pharmaceutical compositions and disease treatment.

As this is a patent application, it does not impose direct regulatory obligations on companies. However, it signifies potential future intellectual property and market exclusivity for a specific cancer treatment approach. Companies involved in oncology drug development, particularly those working with WEE1 inhibitors or HRD biomarkers, should be aware of this filing for competitive intelligence and potential licensing or collaboration opportunities.